Anita Brikman: Inside the Plasma Donation Journey
Anita Brikman, Chief Executive Officer at Plasma Protein Therapeutics Association (PPTA), shared a post on LinkedIn:
“This week, I had the opportunity to experience the plasma donation journey firsthand during a visit to a BioLife Plasma Services donation center.
What made the experience particularly meaningful was the chance to meet other donors and hear what inspired them to donate.
Each person had their own story, but they shared a common understanding that their donation could help someone they may never meet.
It was a powerful reminder that the plasma journey starts with people willing to make a difference.
I would like to thank Karine Stephens, Global Head of BioLife Plasma Services for joining me, and Hema Tallman, Senior Vice President, Global Head of Commercial Plasma Portfolio for helping make the visit possible.
I extend my appreciation to the entire team.
It was inspiring to see how donors are truly at the heart of their mission, and to see that commitment reflected throughout the center, from the warm welcome to the focus on creating a positive and friendly experience for me.
I left with an even deeper appreciation for the many people who make the plasma ecosystem possible, from the donors to the teams at the plasma donation centers who care for them with professionalism every step of the way.
Plasma cannot be manufactured, and every donation represents an opportunity to help provide life-changing medicines to patients with rare and serious conditions.
As we look ahead to International Plasma Awareness Week (IPAW 2026), this visit was a timely reminder of why raising awareness matters: Plasma powers possibility, and that possibility begins with every donor who chooses to give.
I hope this post inspires someone reading this to consider plasma donation.”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series